Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check21 days agoChange DetectedThe page has been updated to reflect a new study version with a revised date and additional details about the study's criteria and endpoints, while previous versions and dates have been removed.SummaryDifference2%
- Check28 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check44 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
- Check51 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check65 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check73 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.